<code id='58CD03826D'></code><style id='58CD03826D'></style>
    • <acronym id='58CD03826D'></acronym>
      <center id='58CD03826D'><center id='58CD03826D'><tfoot id='58CD03826D'></tfoot></center><abbr id='58CD03826D'><dir id='58CD03826D'><tfoot id='58CD03826D'></tfoot><noframes id='58CD03826D'>

    • <optgroup id='58CD03826D'><strike id='58CD03826D'><sup id='58CD03826D'></sup></strike><code id='58CD03826D'></code></optgroup>
        1. <b id='58CD03826D'><label id='58CD03826D'><select id='58CD03826D'><dt id='58CD03826D'><span id='58CD03826D'></span></dt></select></label></b><u id='58CD03826D'></u>
          <i id='58CD03826D'><strike id='58CD03826D'><tt id='58CD03826D'><pre id='58CD03826D'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:6234
          An FDA sign — health policy coverage from STAT
          Sarah Silbiger/Getty Images

          WASHINGTON — There’s about to be a new acronym in town.

          The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.

          advertisement

          That overhaul includes a new name: Meet the Office of Inspections and Investigations.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          New guidelines on severe brain injury complicate already difficult decisions
          New guidelines on severe brain injury complicate already difficult decisions

          AdobeWhensomeonesustainsaseriousbraininjuryandisunresponsive,howsooncandoctorssaywhetherheorshehasac

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          With fresh data, a dynamic duo powers Eli Lilly to new heights

          EliLillyCEODavidRicks(left)andChiefScientificOfficerDanielS.SkovronskyMollyFergusonforSTATThepartner